Lymphoblastic Lymphoma clinical trials

Explore recruiting lymphoblastic lymphoma clinical trials.

Recruiting lymphoblastic lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lymphoblastic Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma

Poland, Italy, Denmark, Czechia, Germany, Slovakia +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children – sub protocol B

Netherlands, Spain, Norway, Sweden, Denmark, Germany +5 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol C

Denmark, Norway, Italy, Netherlands, Finland, Spain +5 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children - Sub-protocol D

Netherlands, Denmark, Finland, Germany, Italy, Spain +5 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/Lymphoma

Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Safety and efficacy of hCD1a-CAR T (OC-1) therapy, in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)_CARxALL

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Lymphoblastic Lymphoma trials by city

Lymphoblastic Lymphoma in Toronto Lymphoblastic Lymphoma in Vancouver Lymphoblastic Lymphoma in Montreal Lymphoblastic Lymphoma in Calgary Lymphoblastic Lymphoma in Edmonton Lymphoblastic Lymphoma in Ottawa Lymphoblastic Lymphoma in Winnipeg Lymphoblastic Lymphoma in Quebec City Lymphoblastic Lymphoma in Hamilton Lymphoblastic Lymphoma in Kitchener Lymphoblastic Lymphoma in London Lymphoblastic Lymphoma in Halifax Lymphoblastic Lymphoma in New York Lymphoblastic Lymphoma in Los Angeles Lymphoblastic Lymphoma in Chicago Lymphoblastic Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease